FIELD: medicine.
SUBSTANCE: method involves applying system based on silicon. The system has a mixture of at least one silicon glue of high adhesiveness showing its effectiveness under press action and at least one silicon glue of moderate adhesiveness showing its effectiveness under press action as basic gluing ingredients. The transcutaneous therapy system has surface of 10 to 40 cm2 and comprises 0.1-3.15 mg/cm2 of Rotigotine in free base form as active ingredient for preparing antiparkinsonian drug. The present invention improves patient health state evaluated as 2 units or higher according to UPDRS, part II and III, when compared to placebo, during at least 7 weeks after injection as a result of improved Rotigotine release parameters and provided Rotigotine dose-activity relation optimum.
EFFECT: enhanced effectiveness of treatment.
13 cl, 2 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PERCUTANEOUS THERAPEUTIC SYSTEM FOR TREATMENT OF PARKINSON'S DISEASE INDUCING HIGH ROTIGOTIN PLASMA LEVEL | 2002 |
|
RU2272625C2 |
| DEVICE FOR TRANSDERMAL INTRODUCTION OF ROTIGOTINE IN ORGANISM IN FORM OF BASE | 2003 |
|
RU2340339C2 |
| FORMULATION FOR TRANSEPICUTAL ADMINISTRATION IN TREATMENT OF RESTLESS LEGS SYNDROME | 2003 |
|
RU2301063C2 |
| IONTOPHORETIC ROTIGOTINE DELIVERY IN TREATMENT FOR PARKINSON'S DISEASE | 2003 |
|
RU2339372C2 |
| THERMOFUSIBLE TTS FOR APPLYING ROTIGOTIN | 2003 |
|
RU2304434C2 |
| IONOPHORETIC DELIVERY OF ROTIGOTINE FOR TREATMENT OF PARKINSON DISEASE | 2008 |
|
RU2478383C2 |
| TRANSCUTANEOUS MEDICATION FOR TREATING PARKINSON DISEASE CONTAINING COMBINATIONS OF ACTIVE SUBSTANCES | 2004 |
|
RU2397757C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 2006 |
|
RU2450805C2 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
